99 results
8-K
EX-99.1
HRMY
Harmony Biosciences Holdings Inc
22 Feb 24
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
7:45am
product candidates, including those we are developing with Bioprojet; our failure to achieve the potential benefits of the 2022 LCA with Bioprojet; our … ability to recognize the intended benefits of our acquisition of Zynerba Pharmaceuticals; our estimates regarding expenses, future revenue, capital
8-K
EX-99.1
ajucx4 wvi7tv7
8 Jan 24
Results of Operations and Financial Condition
8:30am
8-K/A
EX-99.1
h20nayff3af21
7 Dec 23
Consolidated Financial Statements
4:06pm
8-K/A
EX-99.2
kqyx3bs
7 Dec 23
Consolidated Financial Statements
4:06pm
8-K/A
EX-99.2
fkh9cj9r
7 Dec 23
Consolidated Financial Statements
4:06pm
8-K
EX-99.1
ia14jhzdr zpsl
31 Oct 23
Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results
7:45am
8-K
EX-99.1
106bl1 o4
13 Oct 23
Harmony Biosciences Announces Topline Data from Phase 3 Intune Study Evaluating Pitolisant In Patients with Idiopathic Hypersomnia
8:15am
SC TO-T/A
EX-99
5huvanyvg1n5h0eq
11 Oct 23
Third party tender offer statement (amended)
8:31am
8-K
EX-99.1
79vtpeq 55i4ouuwx
11 Oct 23
Harmony Biosciences Completes Acquisition of Zynerba
8:15am
8-K
EX-10.2
niaqeziupckbs1s0bja
5 Oct 23
Departure of Directors or Certain Officers
4:15pm
8-K
EX-10.1
afgw ut11j6pp
5 Oct 23
Departure of Directors or Certain Officers
4:15pm
SC TO-T/A
EX-99
ffm bwtet42w5vw
27 Sep 23
Third party tender offer statement (amended)
8:12am
8-K/A
EX-2.1
71dx4ux8u l0xyd5ve
14 Sep 23
Entry into a Material Definitive Agreement
4:42pm
SC TO-T
EX-99
xpf0a4e73z2d va
28 Aug 23
Third party tender offer statement
8:23am
SC TO-T
EX-99
2kuy8fqbm674zmkrc
28 Aug 23
Third party tender offer statement
8:23am